TYRA
Tyra Biosciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +1.6% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +1 | 26.24M | $838.62M | +9 | −8 |
| Q1 2026 | 71 | +10 | 23.52M | $900.04M | +12 | −2 |
| Q4 2025 | 61 | -1 | 13.06M | $343.28M | +1 | −2 |
| Q3 2025 | 17 | 0 | 6.63M | $92.78M | n/a | n/a |
| Q2 2025 | 14 | +2 | 5.95M | $56.99M | +2 | n/a |
| Q1 2025 | 9 | -1 | 2.08M | $19.36M | n/a | −1 |
| Q4 2024 | 10 | +1 | 1.73M | $24.09M | +2 | −1 |
| Q3 2024 | 8 | +5 | 939.26K | $22.08M | +5 | n/a |
| Q2 2024 | 3 | n/a | 674.98K | $10.79M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 1.87M | -1.3% | $26.15M | 0.0% | ▼ Trim | 2 | SEC ↗ ×9 |
| 2 | The Vanguard Group ✦ (passive) | 1.52M | +8.4% | $21.27M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 3 | Marshall Wace ✦ | 602.01K | +40.6% | $8.42M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 597.45K | +5.3% | $8.36M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 428.47K | +2.3% | $5.99M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Morgan Stanley ✦ | 322.14K | n/a | $4.51M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 7 | Point72 Asset Management ✦ | 282.03K | +25.5% | $3.95M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 199.44K | +88.5% | $2.79M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 170.10K | +25.9% | $2.38M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | JPMorgan Chase ✦ | 148.46K | n/a | $2.08M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Millennium Management ✦ | 144.02K | -64.7% | $2.01M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 111.29K | -48.5% | $1.56M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Goldman Sachs Group ✦ | 100.15K | n/a | $1.40M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Wellington Management ✦ | 82.87K | -19.6% | $1.16M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 15 | AQR Capital Management ✦ | 28.07K | -2.2% | $392,686 | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 16 | T. Rowe Price ✦ | 12.80K | +6.5% | $180,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Fidelity (FMR) ✦ | 12.53K | +2.7% | $175,280 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 163 holders, 65.87M shares, $2.48B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 972 sh @ 20.58 · $20,000
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
19.9% of class · View original SEC filing ↗